Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

June 30, 2016

Conditions
Blepharitis
Interventions
DRUG

KPI-121

KPI-121 drug product will be supplied in 0.25% strength as a suspension in opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arm will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.

DRUG

Vehicle

The vehicle control has the same composition as KPI-121 0.25% ophthalmic suspension except it does not contain loteprednol etabonate. The vehicle is essentially isotonic and is buffered to maintain pH 5.0 - 7.0. It is a sterile, aqueous solution supplied in the same white, low-density polyethylene plastic dropper bottle with the same white, controlled-drop polyethylene tip and white polypropylene closure as KPI-121 0.25% ophthalmic suspension.

Trial Locations (8)

11793

South Shore Eye Center, LLP, Wantagh

23502

Virginia Eye Consultants, Norfolk

44115

Abrams Eye Center, Cleveland

64111

Tauber Eye Center, Kansas City

90505

Wolstan & Goldberg Eye Associates, Torrance

90701

Sall Research Medical Center, Artesia

91345

North Valley Eye Medical Group, Mission Hills

35294-0010

UAB School of Optometry, Birmingham

Sponsors
All Listed Sponsors
lead

Kala Pharmaceuticals, Inc.

INDUSTRY

NCT02218489 - Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease | Biotech Hunter | Biotech Hunter